Revolutionizing ovarian cancer treatment: cryptic antigens as the next breakthrough in immunotherapy.
作者信息
Khatri Nisha, Kumar Harendra, Kumar Bharat
机构信息
Liaquat University of Medical and Health sciences, Jamshoro, Pakistan.
Dow University of Health Sciences, Karachi, Pakistan.
出版信息
Ann Med Surg (Lond). 2025 May 20;87(7):4003-4004. doi: 10.1097/MS9.0000000000003372. eCollection 2025 Jul.
Abstract
摘要
相似文献
1
Revolutionizing ovarian cancer treatment: cryptic antigens as the next breakthrough in immunotherapy.变革卵巢癌治疗：隐匿抗原成为免疫疗法的下一个突破点。
Ann Med Surg (Lond). 2025 May 20;87(7):4003-4004. doi: 10.1097/MS9.0000000000003372. eCollection 2025 Jul.
2
Antigen-specific active immunotherapy for ovarian cancer.卵巢癌的抗原特异性主动免疫疗法。
Cochrane Database Syst Rev. 2018 Sep 10;9(9):CD007287. doi: 10.1002/14651858.CD007287.pub4.
3
Antigen-specific active immunotherapy for ovarian cancer.卵巢癌的抗原特异性主动免疫疗法。
Cochrane Database Syst Rev. 2014 Sep 17(9):CD007287. doi: 10.1002/14651858.CD007287.pub3.
4
Antigen-specific active immunotherapy for ovarian cancer.卵巢癌的抗原特异性主动免疫疗法。
Cochrane Database Syst Rev. 2010 Jan 20(1):CD007287. doi: 10.1002/14651858.CD007287.pub2.
5
Engineered T cells for Colorectal Cancer.结直肠癌细胞工程化 T 细胞
Immunotherapy. 2024;16(14-15):987-998. doi: 10.1080/1750743X.2024.2391733. Epub 2024 Sep 4.
6
Gene signature of m6A-related targets to predict prognosis and immunotherapy response in ovarian cancer.m6A 相关靶点的基因特征可预测卵巢癌的预后和免疫治疗反应。
J Cancer Res Clin Oncol. 2023 Feb;149(2):593-608. doi: 10.1007/s00432-022-04162-3. Epub 2022 Sep 1.
7
Worldwide Research Trends on the Immunotherapy-Based Treatment of Ovarian Cancers: A Bibliometric and Visual Analysis.基于免疫疗法的卵巢癌治疗的全球研究趋势：文献计量与可视化分析
J Multidiscip Healthc. 2025 Jul 25;18:4197-4217. doi: 10.2147/JMDH.S526280. eCollection 2025.
8
Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trial.作为一线治疗接受化疗免疫疗法的晚期卵巢癌患者中，原发肿瘤的肿瘤-基质比例作为预后生物标志物：来自NeoPembrOV/GINECO II期随机试验的分析
ESMO Open. 2025 Jun;10(6):105104. doi: 10.1016/j.esmoop.2025.105104. Epub 2025 Jun 4.
9
[Immunotherapy in epithelial ovarian carcinoma: hope and reality].[上皮性卵巢癌的免疫治疗：希望与现实]
J Gynecol Obstet Biol Reprod (Paris). 2014 Mar;43(3):198-210. doi: 10.1016/j.jgyn.2013.10.004. Epub 2013 Nov 11.
10
Role of Immunotherapy in Ovarian Cancer: Advances, Challenges, and Future Perspectives.免疫疗法在卵巢癌中的作用：进展、挑战及未来展望
Cancer Treat Res. 2025;129:187-220. doi: 10.1007/978-3-031-97242-3_10.
本文引用的文献
1
Theranostics aspect of extracellular vesicle in cancer liquid biopsy.癌症液体活检中细胞外囊泡的诊疗学研究现状
J Liq Biopsy. 2024 Jan 5;3:100139. doi: 10.1016/j.jlb.2024.100139. eCollection 2024 Mar.
2
Immunogenic cryptic peptides dominate the antigenic landscape of ovarian cancer.免疫原性隐蔽肽主导卵巢癌的抗原格局。
Sci Adv. 2025 Feb 21;11(8):eads7405. doi: 10.1126/sciadv.ads7405. Epub 2025 Feb 19.
3
Li-Fraumeni Syndrome: A Rare Genetic Disorder.李-弗劳梅尼综合征：一种罕见的遗传性疾病。
Cureus. 2022 Sep 16;14(9):e29240. doi: 10.7759/cureus.29240. eCollection 2022 Sep.
4
Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using GLOBOCAN 2020.今天和明天的卵巢癌：基于 GLOBOCAN 2020 的全球按世界区域和人类发展指数评估。
Int J Cancer. 2022 Nov 1;151(9):1535-1541. doi: 10.1002/ijc.34002. Epub 2022 Mar 30.
5
Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer.肿瘤异质性和微环境对卵巢癌患者新抗原识别的影响。
Cancer Immunol Immunother. 2021 May;70(5):1189-1202. doi: 10.1007/s00262-020-02764-9. Epub 2020 Oct 29.
6
Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors.鉴定和靶向人类肿瘤抗原用于实体瘤的 T 细胞为基础的免疫治疗。
Cancer Cell. 2020 Oct 12;38(4):454-472. doi: 10.1016/j.ccell.2020.07.013. Epub 2020 Aug 20.
7
Epidemiology of ovarian cancer.卵巢癌的流行病学。
Chin Clin Oncol. 2020 Aug;9(4):47. doi: 10.21037/cco-20-34. Epub 2020 Jun 30.
8
The role of immune checkpoint inhibition in the treatment of ovarian cancer.免疫检查点抑制在卵巢癌治疗中的作用。
Gynecol Oncol Res Pract. 2016 Nov 24;3:11. doi: 10.1186/s40661-016-0033-6. eCollection 2016.
9
Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.卵巢癌中低突变负荷可能限制新抗原靶向疫苗的效用。
PLoS One. 2016 May 18;11(5):e0155189. doi: 10.1371/journal.pone.0155189. eCollection 2016.
10
Cryptic T-cell epitopes and their role in the pathogenesis of autoimmune diseases.
Br J Rheumatol. 1997 Nov;36(11):1144-50. doi: 10.1093/rheumatology/36.11.1144.
Zotero 插件